Delivered Digitally - European Standard Time

Immutep will participate in the virtual Bio-Europe 2020 conference.

Immutep will participate in the virtual ESMO 2020 conference.

Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview.

Presentation Time (EDT): 15^th September, 9:30 to 9:50 AM

Click here for the video presentation held by Marc Voigt (CEO)

Venue: Taipei Nangang Exhibition Center, Hall 2, 4F, Taipei City 11568, Taiwan

Immutep will participate in the new virtual event format.

Immutep will participate in the new virtual event format and will present:

“Initial results from a Phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab”

&

"Open label, phase I study evaluating feasibility and safety of subcutaneous IMP 321
(a soluble LAG 3 protein, eftilagimod alpha) combined with avelumab in advanced stage
solid tumor entities results from stratum D of the INSIGHT platform trial"

Click here for the "TACTI-002" poster which will be presented at the virtual event - ASCO 2020

Click here for the "Insight" poster which will be presented at the virtual event - ASCO 2020

Immutep will participate in the virtual IOIF conference.

Venue: Hub27 Berlin, Messedamm 22, 14055, Berlin, Germany

Venue: San Diego Convention Center, San Diego, California, USA

Immutep will present this AIPAC data in a global webcast, details are as follows:

Date & Time: Thursday, March 26^th, 8am Australian Eastern Daylight Time / Wednesday, March 25^th, 5pm US Eastern Daylight Time

Register: Interested parties can register via a link to the webcast on the Company’s website or via the following link: http://public.viavid.com/index.php?id=138665

Questions: Investors are invited to submit questions in advance via immutep@citadelmagnus.com.

A replay of the webcast will also be available at www.immutep.com from the day after the event.

Click here for AIPAC Global Webcast Slides

The Company will present the interim TACTI-002 data and provide a further update on its clinical programs in a global webcast. The details for the webcast are as follows:

Date & Time: Wednesday, February 26, 2020, 8:00 am Australian Eastern Daylight Time / Tuesday, February 25, 2020, 4:00 pm US Eastern Daylight Time

Register: Interested parties can register via a link to the webcast on the Company’s website or via the following link:
https://fnn.webex.com/fnn/onstage/g.php?MTID=e11208a0ff7fcccaca4d5e4b8a14e988f

Questions: Investors are invited to submit questions in advance via immutep@citadelmagnus.com.

A replay of the webcast will also be available at www.immutep.com from the day after the event.

Venue: City Cube Berlin, Messedamm 26, 14055 Berlin, Germany

Venue: Westin St. Francis Hotel | San Francisco, California, USA

Venue:  Henry B. Gonzalez Convention Center, 900 E Market St, San Antonio, Texas, USA

Click here to view the poster which will be presented at SABCS.

Venue: CCH - Congress Center Hamburg, Am Dammtor / Marseiller Str., 20355 Hamburg, Germany

https://www.das-neue-cch.de

The company will have presentations at the conference and representatives will be attending.

Venue: Gaylord National Hotel & Convention Center in National Harbor, 201 Waterfront St, Forest Heights, MD 20745, USA

https://www.nationalharbor.com/gaylord-national/

Click here for the "TACTI-002" poster which will be presented at the SITC 2019

Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update.  

Venue: Melbourne Convention & Exhibition Centre, Melbourne VIC 3006, Australia

https://www.ausbiotechinvestment.com.au/event-details 

Day 1 – Tuesday, 15th October/ 2.50 p.m.

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

A soluble LAG-3 protein (eftilagimod alpha) with an anti-PD-1 antibody (pembrolizumab): a new combination in immuno-oncology

Click here for full agenda

Venue: Basel Congress Centre, Basel, Switzerland

Representatives of the company will be attending the conference.

Venue:

www.firabarcelona.com

Fira Gran Via, Barcelona
Av. Joan Carles I, 64
08908 L'Hospitalet de Llobregat, Spain

Click here for the "TACTI-002" poster which will be presented at the ASCO 2019

Click here for the "Insight Trial" poster which will be presented at the ASCO 2019

Venue: McCormick Place, Chicago, IL, USA

Conference Day 2: Friday 17th May 2019/ 11.25.a.m.

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

Combining a soluble LAG-3 protein with an anti-PD-1 antibody in phase I-II trials

Click here for the Presentation at World Advanced Therapies & Regenerative Medicine Congress & Expo 2019

Venue: Business Design Centre, London, UK

Frédéric Triebel, CSO & CMO of Immutep, will participate in a panel discussion.

Venue: The New York Academy of Sciences, New York, New York, USA

Venue: San Diego Convention Center, San Diego, California, USA

Day 2 – Tuesday 5th March/ 3.00 p.m.  

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

Two ACTive Immunotherapies (TACTI): Results of a Phase I trial with metastatic melanoma patients

click here for presentation

Venue:  Grand Hyatt, San Diego, USA

Venue:    San Francisco, California, USA

conference day 1/ 02.00 p.m.

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

Two ACTIve Immunotherapies (TACTI): Results of Phase I Trial With Metastatic Melanoma Patients (TACTI-mel) Treated With a Soluble LAG-3 Receptor (LAG-3lg or Eftilagimod Alpha) as an Antigen Presenting (APC) Activator Combined with Pembrollzumab

Venue: The Sofitel Berlin Kurfuerstendamm, Berlin, Germany

Marc Voigt, CEO of Immutep, will present a corporate overview and business update.

Venue: Macquarie Office -  Sydney, Australia

click here for agenda

The company will have presentations at the conference and representatives will be attending.

Venue:    Walter E. Washington Convention Center, 801 Mt Vernon Pl NW, Washington, D.C., DC 20001, USA

Dr. Victoria Atkinson (Principal Investigator TACTI-mel) speaks on the subject:

"Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma."

Venue: Manchester Central Convention Complex, Manchester, United Kingdom

Representatives of the company will be attending the conference.

Venue:   Messe Munich, Messegelände, 81823 Munich, Germany, www.messe-muenchen.de

Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update at 3:30pm ET on Tuesday, October 2, 2018, with one-on-one meetings held throughout the day. The presentation will be webcast live and available for replay via the investor relations section of the company’s website at www.immutep.com.

Listen to the webcast “Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference”

Download "Ladenburg 2018 HC Conference Immutep Presentation"

Marc Voigt, CEO of Immutep, will present a corporate overview and business update with one-on-one meetings held throughout the day. 

Venue:  Millenium Broadway Hotel & Conference Center, NY, USA

Press release: click here

Download "Newsmaker Immutep Corporate Presentation"

Listen to the webcast “Immutep Newsmakers Presentation” from September 7th, 2018

 - the largest networking event for life sciences and healthcare industries in the German capital region -

Venue:    Ludwig Erhard Haus, Fasanenstraße 85, Berlin, Germany

Frédéric Triebel speaks on the subject:

“Two ACTIve Immunotherapies in melanoma (TACTI-mel): results of a phase I trial with metastatic melanoma patients treated with a soluble LAG-3 receptor (LAG-3Ig or eftilagimod alpha) as an antigen presenting (APC) activator combined with pembrolizumab.”

Frédéric Triebel speaks on the subject:
“LAG-3: the next immune checkpoint after CTLA-4 and PD-1/PDL-1?”

Venue:  bbc (Berlin Congress Center), Alexanderstr. 11, 10178, Berlin, Germany

Venue:  McCormick Place, Chicago, IL, USA

Company presentation by Jay R. Campbell at 9.00am EDT on Monday, April 9^th

Venue:  Essex House, New York, NY, USA